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ABSTRACT
Background
Drug development is ideally a logical sequence in which information from small early studies
(Phase I) is subsequently used to inform and plan larger, more definitive studies (Phases II–IV).
Phase I trials are unique because they generally provide the first evaluation of new drugs in
humans. The conduct and dissemination of Phase I trials have not previously been empirically
evaluated. Our objective was to describe the initiation, completion, and publication of Phase I
trials in comparison with Phase II–IV trials.
Methods and Findings
We reviewed a cohort of all protocols approved by a sample of ethics committees in France
from January 1, 1994 to December 31, 1994. The comparison of 140 Phase I trials with 304
Phase II–IV trials, showed that Phase I studies were more likely to be initiated (133/140 [95%]
versus 269/304 [88%]), more likely to be completed (127/133 [95%] versus 218/269 [81%]), and
more likely to produce confirmatory results (71/83 [86%] versus 125/175 [71%]) than Phase II–IV
trials. Publication was less frequent for Phase I studies (21/127 [17%] versus 93/218 [43%]), even
if only accounting for studies providing confirmatory results (18/71 [25%] versus 79/125 [63%]).
Conclusions
The initiation, completion, and publications of Phase I trials are different from those of other
studies. Moreover, the results of these trials should be published in order to ensure the integrity
of the overall body of scientific knowledge, and ultimately the safety of future trial participants
and patients.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
New drugs are developed following a logical, step-by-step
procedure in which ﬁndings from small early studies are used
to inform and design subsequent larger studies [1]. To
develop new drugs efﬁciently, it is essential to identify their
properties in the early stages of development, and then
construct a research plan adapted to these characteristics
[1,2].
The different stages of clinical trials involving pharma-
ceutical interventions are classiﬁed into four phases (Box 1)
[1,2]. Phase I trials provide an early evaluation of short-term
safety, tolerability, pharmacokinetics, and sometimes efﬁcacy.
Phase II studies explore therapeutic efﬁcacy in patients,
whilst Phase III studies aim to conﬁrm therapeutic beneﬁt.
Phase IV trials are designed to optimize the drug’s use in
clinical practice. These deﬁnitions involve a degree of
subjective judgment, and substantial overlap exists between
terms. More recently, a ﬁfth phase was created for explor-
atory ﬁrst-in humans studies without therapeutic or diag-
nostic intent [3].
In France, all trials involving human beings must be
submitted to a research ethics committee (REC) by the
principal investigator in accordance with the Huriet-Se ´ru-
sclat Act of 1988 [4]. Phase I trials are more closely monitored
than other phases of drug development because they
constitute the ﬁrst introduction of a new drug undergoing
investigation in humans. Moreover, they are usually con-
ducted in healthy volunteers to assess their safety [4],
although new therapies for some diseases such as cancer or
HIV infection are understandably often ﬁrst investigated in
patients.
A large number of reviews have previously assessed the fate
of research studies and publication bias but to our knowl-
edge, none have been focused on Phase I trials across
specialized ﬁelds [5–8]. We reviewed a cohort of clinical trial
protocols in France to describe the initiation, completion,
and publication of Phase I trials, and to determine whether
these outcomes differed from those of Phase II–IV trials.
Methods
Study Cohort
In 1994, there were 48 RECs in France; each REC was
responsible for a speciﬁc administrative geographical area,
was evaluating equivalent types of protocols, and was
representative of the biomedical research carried out locally.
The principal investigator (FC) selected 25 RECs on the basis
of geographic criteria to ensure a representative cross-
section. Consent was obtained from the chairperson of all
selected committees to participate in the study.
We included all pharmaceutical trials (i.e., studies that
prospectively assigned drug interventions to humans to
evaluate their effects on health outcomes) that were newly
approved between January 1, 1994 and December 31, 1994 by
any of the 25 participating French committees. In France, each
trial is submitted by the principal investigator to only one REC
nationally, it was therefore impossible for a trial to be counted
twice in our cohort. No sample size calculation was made.
Data Collection
Each REC was responsible for collecting its own data from
committee ﬁles and questionnaires were sent to investigators.
A research assistant from each REC attended a formal
training session on the abstraction of study characteristics
in June 2000. An identiﬁcation number was assigned to each
trial protocol to ensure anonymity, and all collected data
were then forwarded to the coordinating centre where the
data were checked and analyzed. RECs were contacted for any
missing or incorrect data. Anonymity was not preserved in
cases where the investigator provided full journal references.
Data were collected from committee ﬁles, including trial
protocols, about the type of investigator, sponsor, participant
population (healthy volunteers versus patients), study phase,
intervention, design, study sites, estimated sample size,
duration, and amendments after trial initiation.
Box 1
International Conference on Harmonization of Definitions of Trial Phases
for Pharmaceutical Trials [1,2]
Phase I
Studies conducted in Phase I typically involve one or a combination of
the following objectives:
(a) to determine the tolerability of the dose range expected and the
nature of adverse reactions that can be expected;
(b) to characterize a drug’s absorption, distribution, metabolism, and
excretion and also to assess the clearance of the drug and to anticipate
possible accumulation of potential efficacy that may guide the dosage
and dose regimen;
(c) to provide early estimates of activity and potential efficacy that may
guide the dosage and dose regimen in later studies;
(d) to provide an early measurement of drug activity when drug activity
is readily measurable with a short duration of drug exposure in patients
at this early stage.
Phase I studies involve a small number of persons.
Phase II
The primary objective of Phase II studies is to explore therapeutic
efficacy in patients. Phase II studies are typically conducted in a group of
patients who are selected by relatively narrow criteria, leading to a
relatively homogeneous population, and who are closely monitored.
An important goal for this phase is to determine the dose(s) and regimen
for Phase III trials.
Additional objectives of clinical trials conducted in Phase II may include
evaluation of potential study endpoints, therapeutic regimens (including
concomitant medications), and target populations (e.g., mild versus
severe disease) for further study in Phase II or III.
These studies are performed on several hundred volunteers, including a
limited number of patients with the target disease or disorder.
Phase III
The primary objective of Phase III studies is to demonstrate or confirm
therapeutic benefit. Studies in Phase III are designed to confirm the
preliminary evidence accumulated in Phase II that a drug is safe and
effective for use in the intended indication and recipient population.
These studies are intended to provide an adequate basis for marketing
approval. Studies in Phase III may also further explore the dose–response
relationship, or explore the drug’s use in wider populations, in different
stages of disease, or in combination with another drug.
These studies are performed on groups of patients large enough to
identify clinically significant responses.
Phase IV
Phase IV studies after-drug approval and marketing and are often
important for optimizing the drug’s use. Commonly conducted studies
include additional drug interaction, dose–response, or safety studies and
studies designed to support use under the approved indication, e.g.,
mortality/morbidity studies, epidemiological studies.
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Phase I Trials’ Inadequate DisseminationUsing questionnaires mailed to the principal investigators
in January 2001, we also collected follow-up data on funding,
trial status (initiated or completed), the actual duration of the
study and sample size, study results (conﬁrmation or invalid-
ation of the study hypothesis, inconclusive, or no hypothesis
tested), format for dissemination (scientiﬁc article, oral
presentation, internal report, book chapter, doctoral dis-
sertation, or abstract), and reasons for not publishing.
Deﬁnitions of terms are provided in Box 2 [9,10]. In cases
where no response was forthcoming, principal investigators
were contacted up to six times by mail or phone. Where no
answer could be obtained, the REC contacted the sponsor in
August 2002. We recorded the reason for nonresponse. Due
to the requirement for the anonymous coding of data,
publication status in bibliographic databases was not veriﬁed.
Ethical Considerations
We conducted this study according to the French law on
epidemiological and descriptive studies; as there was no
intervention on humans, REC approval was not required [4].
We collected data anonymously to respect the conﬁdentiality
of investigators and drug companies, and consent was not
required as no patient information was collected.
Statistical Methods
The primary outcome of our study was the proportion of
Phase I and Phase II–IV trials published (see deﬁnition in Box
2). As secondary outcomes, we evaluated trial characteristics,
initiation and completion rates, and time to publication. The
magnitude of publication bias was evaluated in an exploratory
analysis. A logistic regression for publication was performed
to evaluate the interaction between trial phases and results.
We tabulated descriptive data for all variables (medians and
10th–90th percentile range, proportions). We used chi-square
or Fisher’s exact test to compare categorical data, and Mann-
Whitney tests for continuous variables. We excluded studies
with missing data from the analysis on the main endpoints.
To compare the time to publication between Phase I and
Phase II–IV trials, we performed a Kaplan-Meier survival
analysis using the time from the date of approval by the REC
to the date of ﬁrst publication. The date of ﬁrst publication
was the effective date of publication for published studies and
date of questionnaire completion for ‘‘in-press’’ studies.
Unpublished studies were censored at the questionnaire
completion date.
We included all completed studies with a publication date
or a censoring date available. To ensure homogeneity in the
follow-up, protocols with a time to publication greater than 8
y were censored at 8 y from approval. We used a log-rank test
to compare survival curves.
We used SAS software for all analyses, considering
associations to be statistically signiﬁcant when two-sided p-
values were , 0.05.
Results
In 1994, the 25 ethics committees evaluated 723 drug trial
protocols. 56 protocols were excluded for various reasons
(approved in 1993 [n ¼ 38], withdrawn before approval [n ¼
11], not approved [n¼5], or approval not required by law [n¼
2]). Phase I trials accounted for 24% (n ¼ 163) of the
remaining 667 protocols (Figure 1).
We received questionnaire responses for 67% (444/667) of
the trials, which constituted our ﬁnal cohort for analysis. Data
were unavailable for 223 questionnaires: ten were unsuitable
for statistical analysis, 85 investigators did not respond, 49
declined participation, 45 declared that the ﬁle was lost, 27
had moved with no identiﬁable address, and seven had
retired. Response rates differed signiﬁcantly between trial
phases: 86% (140/163) for Phase I trials and 60% (304/504) for
Phase II–IV trials (p , 0.001).
Trial Characteristics
Administration and conduct differed signiﬁcantly between
Phase I and Phase II–IV trials (Tables 1 and 2). Phase I trials
were more frequently led by nonacademic researchers (56%
versus 6%), sponsored by industry, conducted in accredited
Phase I research units, and conducted at a single study centre.
Phase I trials also had a shorter planned duration and smaller
estimated sample sizes compared to other trial phases (Table
3). Furthermore, Phase I trials were less likely to use a control
group or planned interim analysis.
Initiation and Completion Rates
Approved Phase I trials were more frequently initiated in
comparison with other phases (p ¼ 0.03) (Figure 1). The main
reasons for not beginning a study were mainly the sponsor’s
decision for Phase I and other phases (Figure 1).
The completion rate for initiated studies was signiﬁcantly
greater (p ¼ 0.0004) for Phase I trials compared with other
phases (Figure 1). Among the 50 studies that were terminated
prematurely, the reasons differed between groups: Phase I
studies were mainly stopped because of interim analysis
results or adverse effects, whereas other phases were mainly
stopped because of recruitment problems (Figure 1).
Dissemination of the Results ofCompleted Studies(n¼345)
Information on the dissemination of results was provided
for 99% (126/127) of the completed Phase I, and 94% (204/
218) of completed Phase II–IV trials. Results of Phase I trials
were less often published as journal articles than Phase II–IV
Box 2. Definitions Used
Direction of results: Investigator had to classify their study as a whole: no hypothesis tested, results not known, results confirming study hypothesis
(‘‘confirmatory results’’), results invalidating study hypothesis (‘‘invalidating results’’), results neither confirming nor invalidating study
hypothesis (‘‘inconclusive results’’).
Publication: Study published as a full article in a general or specialized peer-reviewed journal.
Grey literature: Studies published in formats other than scientific papers and not generally accessible through libraries (internal reports, theses,
abstracts, posters) [9]. Book chapters were included as grey literature.
Dissemination: Any kind of results communication (scientific papers and grey literature).
Publication bias: The tendency to publish research based on the direction and statistical significance of study findings [10].
PLoS Medicine | www.plosmedicine.org February 2009 | Volume 6 | Issue 2 | e1000034 0204
Phase I Trials’ Inadequate Disseminationtrials (odds ratio 0.24, 95% conﬁdence interval 0.14–0.41, p ,
0.0001) (Figure 1).
A total of 99 completed studies had to be excluded from the
Kaplan-Meier analysis owing to missing information on dates
(publication or censoring). Phase I studies took a signiﬁcantly
longer time to be published despite shorter study durations.
The medians were not reached but the 10th percentile was, at
4.5 y versus 3.1 y for Phases II–IV (Figure 2 and Table S1).
The reasons provided by principal investigators for non-
publication differed signiﬁcantly between the two groups
(Figure 1): conﬁdentiality was the main reason given for
unpublished Phase I studies.
Among the 105 Phase I and 111 Phase II–IV trials that were
not published as a full journal article, 33 (31%) and 47 (42%),
respectively, were disseminated as grey literature, with internal
reports being the most frequent example of this (Table 4).
Nature of Results and Publication Bias
Hypothesis testing was not conducted in 13/127 (10%) of
completed Phase I trials and in 10/218 (5%) of completed
trials in other phases. Results were unknown or not provided
for 31/127 (24%) of Phase I studies compared to 33/218 (15%)
of other phases. Information on the direction of results was
available for 83/127 (65%) Phase I and 175/218 (80%) Phase
II–IV trials. Phase I study results conﬁrmed the investigators’
clinical hypotheses more often than other phases (Table 3).
Out of the 258 trials with data available on the direction of
results, 255 also had data available on publication status
(Table 3). The interaction between phase and results, i.e.,
differential publication bias, could not be tested as no
inconclusive or invalidating Phase I results were published.
However the model without interaction was well ﬁtted, which
suggests that the interaction would not have been signiﬁcant.
Trials with conﬁrmatory results had signiﬁcantly higher
publication rates than trials with invalidating or inconclusive
results for Phase II–IV trials (64% versus 21%, p , 0.0001,
exclusion of the three studies with no information on
Figure 1. Flow Chart of Studies
doi:10.1371/journal.pmed.1000034.g001
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Phase I Trials’ Inadequate Disseminationpublication), but not signiﬁcantly for Phase I trials (25%
versus 0%, p ¼ 0.18).
Discussion
The main ﬁnding of our study was that Phase I studies were
more often initiated and completed than other phases, but
far less disseminated. Previous studies have described the
outcome of study protocols [5–8], but none has focused on
Phase I trials across specialties, or compared them with other
trial phases. One previous review evaluated the outcome of
Phase I trials submitted to an annual oncology meeting and
found that 67% were subsequently published [11], but studies
submitted to an annual meeting in one specialty ﬁeld might
be not representative of all Phase I studies. Our ﬁndings
conﬁrm the low overall publication rate of clinical trials
found in previous reviews [5–8]. Methodological reviews of
trials should therefore consider analyzing different phases as
distinct subgroups.
The strength of our study was that we conducted a
comprehensive analysis of the pharmaceutical trials approved
in 1994 by half of the RECs in France. Approval by local RECs
is mandatory for any research protocol involving interven-
tions in human beings. Our sample is therefore representa-
tive of the pharmaceutical trials conducted in France.
Several limitations may have affected the results of our
study. The overall response rate of 67% is comparable to
previous methodological surveys of trials [12,13]. The differ-
ential response rate between Phase I and Phase II–IV trials
may have introduced response bias, although it is unclear
whether this would have inﬂuenced our ﬁndings in any given
direction. It is likely that the publication rates found in our
Table 1. Administration of 444 Clinical Trials
Administrative
Category
Subcategory Phase I,
n ¼ 140 (%)
Other Phases,
n ¼ 304 (%)
Chi-Square
p-Value
Sponsor — — — 0.02
Pharmaceutical firm 124 (89) 232 (76) —
Tertiary teaching hospital 9 (6) 39 (13) —
Other public organization 3 (2) 19 (6) —
Other 4 (3) 14 (5) —
Funding — — — 0.05
No funding 4 (3) 22 (7) —
Private funding 125 (89) 247 (81) —
Public funding 8 (6) 15 (5) —
Mixed funding 3 (2) 20 (7) —
Place of research —— — ,0.0001
Phase I specialized unit 115 (82) 12 (4) —
Tertiary teaching hospital 13 (9) 186 (61) —
Tertiary teaching hospital þ private hospital 0 (0) 66 (22) —
Tertiary teaching hospital þ Phase I specialized unit 10 (7) 2 (1) —
Other 2 (2) 38 (12) —
Scope —— — ,0.0001
National, single centre 135 (96) 83 (27) —
National, multicentre 3 (2) 117 (39) —
International multicentre 2 (2) 104 (34) —
doi:10.1371/journal.pmed.1000034.t001
Table 2. Conduct of 444 Clinical Trials
Methodological Category Subcategory Phase I, n ¼ 140 (%) Other Phases, n ¼ 304 (%) p-Value*
Expected duration Expected duration (median in d, IPR80) 61 (30–350) 365 (122–1,096) ,0.0001
Information not provided 20 (14) 97 (32) ,0.0001
Expected sample size Expected sample size (median, IPR80) 16 (9–36) 82 (13–490) ,0.0001
Information not provided 1 (1) 4 (1) NS
Design — — — 0.02
With control group 70 (50) 188 (62) —
Without control group 70 (50) 116 (38) —
Interim analysis planned — — — 0.001
Yes 9 (6) 46 (15) —
No 124 (89) 219 (72) —
Information not provided 7 (5) 39 (13) —
Values are numbers (%) unless otherwise specified.
*, chi-square test for dichotomous variables or Mann-Whitney test for continuous variables.
IPR80, 10th–90th percentile range; NS, not significant.
doi:10.1371/journal.pmed.1000034.t002
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Phase I Trials’ Inadequate Disseminationstudy were overstated if we assume that nonresponders would
be more likely to have trials that were not initiated, not
completed, or unpublished. On the other hand, we did not
conﬁrm the publication status of trials on databases such as
PubMed [14] because the ﬁles were anonymous. This may
have led to an underestimation of publication rates, although
our ﬁndings were similar to previous reviews [5–8]. Moreover,
we were unable to determine the publication date when the
speciﬁc journal reference was not provided.
Some studies were excluded from the survival analysis due
to missing data on dates of publication and dates of
censoring, this analysis should therefore be interpreted with
caution. We chose to exclude these published studies as the
alternative, i.e., including them as censored at time 0, would
mean ignoring the fact that they were published. The same
also applies to the unpublished studies.
Another practical challenge in describing the methodo-
logical characteristics of our cohort was that detailed
information was often missing from the protocols, such as
the expected study duration. One of the reasons could be
related to varying standards in the requirements for protocol
content. We focused on the expected duration and sample
size as information on the actual duration and sample size
was less often available.
The methods and results of our cohort of protocols
approved in 1994 are still relevant, since a median delay of
5 to 8 y is generally observed before publication [6].
Moreover, the publication and prospective registration of
Phase I trials is still subject to discussion in 2008. The poor
dissemination of Phase I trials highlights the importance of
their inclusion in the prospective registration of clinical trials
[15,16]. Whilst several bodies, including the World Health
Organization, the International Committee of Medical
Journal Editors, and the Ottawa Group, have called for their
registration in public registries [17–20], pharmaceutical
companies have expressed their reluctance to disclose
information on early phase trials [21].
Although the results of preliminary Phase I studies might
be considered by some to be less clinically relevant, there are
several ethical and scientiﬁc reasons for making this data
publicly available. Firstly, if access to medical information is a
moral right, then it should be provided irrespective of study
funding and phase [22]. The testing of new pharmaceuticals
on humans is approved by ethics committees based on the
assumption that the inherent risks of trial participation are
Table 4. Grey Literature for the 216 Studies Not Published as Scientific Articles
Publication Type Grey Literature Dissemination Phase I, n ¼ 105 (%) Other Phases, n ¼ 111 (%)
Neither oral presentation nor grey literature 71 (68) 54 (49)
Oral presentation only 1 (1) 10 (9)
Grey literature only 29 (27) 30 (27)
Both oral presentation and grey literature 4 (4) 17 (15)
Grey literature Internal report 28 (85) 31 (66)
Abstract 3 (9) 7 (15)
Doctoral dissertation 2( 6 ) 1( 2 )
Internal report plus abstract 0( 0 ) 2( 4 )
Internal report plus doctoral dissertation 0( 0 ) 1( 2 )
Other (such as book chapter) 0 (0) 5 (11)
doi:10.1371/journal.pmed.1000034.t004
Table 3. Publication Rates for Completed, Hypothesis-Testing
Phase I and Phase II–IV Trials, by Direction of Results
Direction of
Results
Publication
Status
Phase I,
n ¼ 83 (%)
Other Phases,
n ¼ 175 (%)
Confirmatory — 71 (86) 125 (71)
Published 18 (25) 79 (63)
Unpublished 53 (75) 45 (36)
Not provided 0 (0) 1 (1)
Invalidating — 10 (12) 14 (8)
Published 0 (0) 2 (14)
Unpublished 10 (100) 12 (86)
Not provided 0 (0) 0 (0)
Inconclusive — 2 (2) 36 (21)
Published 0 (0) 8 (22)
Unpublished 2 (100) 26 (72)
Not provided 0 (0) 2 (6)
doi:10.1371/journal.pmed.1000034.t003
Figure 2. Time from Ethical Approval to Publication for Phase I Versus
Phase II–IV Trials
doi:10.1371/journal.pmed.1000034.g002
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Phase I Trials’ Inadequate Disseminationbalanced by the beneﬁt of new scientiﬁc knowledge for
society. If this knowledge from Phase I remains hidden, then
any potential risk incurred by trial participation is excessive
and could endanger human lives [23]. Although Phase I trials
are usually safe [24] with very few deaths and severe adverse
events (incidence of related severe adverse events of 0.2%
over a 2-y period among 15,386 participants), adverse events
from Phase I studies are known to be rarely published [25],
which means that this knowledge is unavailable to other
researchers who may unknowingly conduct harmful trials on
similar interventions.
The danger of suppressed knowledge was particularly
evident in the Phase I trial for TGN1412 [26,27], where the
serious adverse reactions suffered by six healthy volunteers in
2006 might have been avoided had the results of a previous
unpublished trial of a similar antibody been known [28].
Since this event, reports have been published to highlight the
need for improved sharing of knowledge from Phase I trials
[29,30]. Publicly accessible trial registers will facilitate the
sharing of information on all trials [15,31], including Phase I
studies [32]. Furthermore, the willingness of journals to
publish Phase I trial results, whether positive or negative,
would help improve their unbiased dissemination [33].
It should also be noted that a third of research programs
for investigational drugs are abandoned for primarily
economic reasons rather than concerns over efﬁcacy or
safety [34,35]. This means that even new drugs that show
clinical promise are often discontinued and the knowledge
lost. Concerns over commercial or competitive advantage
should not obstruct transparency and do not outweigh the
ethical and scientiﬁc responsibilities to disseminate knowl-
edge gained by testing new therapies in humans [26].
To ensure the present and future safety of trial participants
and patients as well as the integrity of scientiﬁc knowledge, all
clinical trials—including Phase I—should be publicly regis-
tered at inception and their results disseminated in a timely
manner [32].
Supporting Information
Table S1. Time from Ethical Approval to Publication for Phase I
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Background. Before a new drug is used to treat patients, its benefits and
harms have to be carefully investigated in clinical trials—studies that
investigate the drug’s effects on people. Because giving any new drug to
people is potentially dangerous, drugs are first tested in a short ‘‘Phase I’’
trial in which a few people (usually healthy volunteers) are given doses of
the drug likely to have a therapeutic effect. A Phase I trial evaluates the
safety and tolerability of the drug and investigates how the human body
handles the drug. It may also provide some information about the drug’s
efficacy that can guide the design of later trials. The next stage of clinical
drug development is a Phase II trial in which the therapeutic efficacy of
the drug is investigated by giving more patients and volunteers different
doses of the drug. Finally, several large Phase III trials are undertaken to
confirm the evidence collected in the Phase II trial about the drug’s
efficacy and safety. If the Phase III trials are successful, the drug will
receive official marketing approval. In some cases, this approval requires
Phase IV (postapproval) trials to be done to optimize the drug’s use in
clinical practice.
Why Was This Study Done? In an ideal world, the results of all clinical
trials on new drugs would be published in medical journals so that
doctors and patients could make fully informed decisions about the
treatments available to them. Unfortunately, this is not an ideal world
and, for example, it is well known that the results of Phase III trials in
which a new drug outperforms a standard treatment are more likely to
be published than those in which the new drug performs badly or has
unwanted side effects (an example of ‘‘publication bias’’). But what
about the results of Phase I trials? These need to be widely disseminated
so that researchers can avoid unknowingly exposing people to
potentially dangerous new drugs after similar drugs have caused adverse
side effects. However, drug companies are often reluctant to disclose
information on early phase trials. In this study, the researchers ask
whether the dissemination of the results of Phase I trials is adequate.
What Did the Researchers Do and Find? The researchers identified 667
drug trial protocols approved in 1994 by 25 French research ethics
committees (independent panels of experts that ensure that the rights,
safety, and well-being of trial participants are protected). In 2001,
questionnaires were mailed to each trial’s principal investigator asking
whether the trial had been started and completed and whether its
results had been published in a medical journal or otherwise
disseminated (for example, by presentation at a scientific meeting).
140 questionnaires for Phase I trials and 304 for Phase II–IV trials were
returned and analyzed by the investigators. They found that Phase I trials
were more likely to have been started and to have been completed than
Phase II–IV trials. The results of 86% of the Phase I studies matched the
researchers’ expectations, but the study hypothesis was confirmed in
only 71% of the Phase II–IV trials. Finally, the results of 17% of the Phase I
studies were published in scientific journals compared to 43% of the
Phase II–IV studies. About half of the Phase I study results were not
disseminated in any form.
What Do These Findings Mean? These findings suggest that the fate of
Phase I trials is different from that of other clinical trials and that there is
inadequate dissemination of the results of these early trials. These
findings may not be generalizable to other countries and may be
affected by the poor questionnaire response rate. Nevertheless, they
suggest that steps need to be taken to ensure that the results of Phase I
studies are more widely disseminated. Recent calls by the World Health
Organization and other bodies for mandatory preregistration in trial
registries of all Phase I trials as well as all Phase II–IV trials should improve
the situation by providing basic information about Phase I trials whose
results are not published in full elsewhere.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
1000034.
  Two recent research articles published in PLoS Medicine—by Ida Sim
and colleagues (PLoS Med e191) and by Lisa Bero and colleagues (PLoS
Med e217)—investigate publication bias in Phase III trials
  The ClinicalTrials.gov Web site provides information about the US
National Institutes of Health clinical trial registry, background
information about clinical trials, and a fact sheet detailing the
requirements of the US Food and Drug Administration (the body
that approves drugs in the USA) Amendments Act 2007 for trial
registration
  The World Health Organization’s International Clinical Trials Registry
Platform is working toward setting international norms and standards
for the reporting of clinical trials (in several languages)
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